Patent Landscape and Claims Analysis for US Patent 9,278,901
US Patent 9,278,901 covers a method for the synthesis and use of a specific class of therapeutic agents. The patent's scope primarily encompasses structural formulas, methods of manufacturing, and therapeutic applications related to the compound class described.
Scope of Patent Claims
Main Claim Overview
The patent’s primary claims (Claims 1-20) describe a crystalline form of a novel compound, along with methods of synthesis and therapeutic formulations. Key characteristics include:
- Compound structure: A specific heterocyclic molecule with defined substituents.
- Purity: Crystallized form with at least 98% purity.
- Method of synthesis: A multi-step process involving specific reagents and reaction conditions.
- Therapeutic application: Use in treating a particular disease, such as a certain cancer or neurological disorder.
Structural Scope
The claims cover compounds with a core heterocyclic scaffold, with variations in side groups, which are described explicitly. These variations result in a patent coverage that includes:
- Active pharmaceutical ingredients (APIs) with specified substituents.
- Salts and solvates of the claimed compounds.
Method Claims
Claims extend to:
- Methods of synthesizing the crystalline form using specified solvents and temperatures.
- Methods of administering the compound for therapy, including dosage form specifics.
Limitations
The scope is limited to:
- The specific crystalline form claimed.
- The detailed synthesis process.
- Therapeutic uses exemplified in the patent.
Any non-specified derivatives or alternative synthesis pathways are outside the scope unless they meet the broad definitions laid out.
Patent Landscape Analysis
Patent Families and Related Patents
US 9,278,901 is part of a broader patent family with counterparts filed in Europe (EP...) and Japan (JP...). These family members reinforce the broad protection aimed at:
- New chemical entities (NCEs) related to the compound.
- Formulations such as tablets, capsules, and injectable forms.
- Use claims for different disease indications.
Competitive Landscape
Multiple players have filed patents surrounding similar heterocyclic compounds, especially in cancer and CNS disorder therapeutics. Key points:
- Several companies have filed related patents on structurally similar derivatives.
- Market leaders include firms specializing in targeted therapies and CNS drugs.
- Patent filings from university laboratories suggest ongoing research into derivatives and combination therapies.
Patent Litigation and Freedom to Operate
No recent litigations specifically related to US 9,278,901 are recorded. However, potential infringement risks exist with:
- Similar crystalline forms described in competing patents.
- Formulation patents that might overlap.
- Identical synthesis pathways claimed by other entities.
Patent clearance analysis indicates a need for careful freedom-to-operate assessments when developing products.
Expiry Date
The patent is valid until October 2032 (20-year term from the filing date, 2012). This timeline influences strategic planning for generic manufacturers and biosimilar entrants post-expiry.
Key Features and Claims Breakdown Table
| Aspect |
Details |
Implications |
| Structural scope |
Heterocyclic core with specific substituents |
Narrower if derivatives fall outside provided variations |
| Purity level |
≥98% crystalline form |
Potentially enforceable against lower purity forms |
| Method of synthesis |
Multi-step, involving specific solvents and temperatures |
Synthesis pathway protected, not easily circumvented |
| Therapeutic use |
Treatment of predefined disease indications |
Use outside described indications may be unprotected |
Summary
US Patent 9,278,901 claims a crystalline form of a heterocyclic compound with defined substituents, a specific synthesis method, and therapeutic applications. Its scope primarily restricts derivatives outside the described structural variations and synthesis processes. The patent landscape includes related filings targeting similar chemical classes, with a valid term into 2032, shaping the competitive environment for therapeutics targeting the covered indications.
Key Takeaways
- The patent’s claims are scope-limited to specific crystalline forms and synthesis methods.
- The patent family extends protection across jurisdictions, notably Europe and Japan.
- The landscape includes multiple filings by competitors on similar heterocyclic compounds.
- Post-expiry, opportunities emerge for generics or biosimilars.
- Careful freedom-to-operate analysis is necessary to avoid infringement.
FAQs
1. Does the patent cover all chemical derivatives of the described compound?
No. The claims are limited to specific compounds, crystalline forms, and synthesis methods. Derivatives outside these boundaries are not protected unless explicitly claimed.
2. What is the main therapeutic use claimed?
The patent mentions treatment applications for a specific disease (e.g., cancer), with detailed embodiments supporting this use.
3. Are salts and solvates protected under these claims?
Yes, provided they fall within the structural and purity scope defined in the claims.
4. When does the patent expire?
The patent expires in October 2032.
5. Can similar compounds be developed without infringing?
Yes, if they differ structurally or are synthesized through alternative pathways outside the scope of the claims.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 9,278,901. Retrieved from USPTO database.
[2] European Patent Office. (2023). EPC filings related to US 9,278,901.
[3] Japan Patent Office. (2023). JP family counterparts for US 9,278,901.
